The takeaway
BlackRock Health Sciences Trust II shows a moderate seasonal pattern over 6 years of data — strongest in November (+3.9%) and softest in February (−2.2%).
Right now
In July, the stock has risen 67% of years, averaging +1.9% — essentially in line with the S&P 500.
The full picture
BlackRock Health Sciences Trust II's most dependable month has been November, higher in 5 of 6 years; February has been its least reliable, up just 17% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 |
Month by month
The stock's clearest edge over the S&P 500 lands in January (+2.3 pts); it has trailed the market most in September (−3.8 pts).
“vs S&P” is BlackRock Health Sciences Trust II’s average for a month minus the S&P 500’s average for that same month — isolating BlackRock Health Sciences Trust II’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, November has closed higher 80% of the time versus 83% across the last 6 years — the pattern is holding.
Figures are the typical (median) November return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The seasonal story is really one month's story — November. It has closed higher in 5 of 6 Novembers, a concentration the rest of the calendar can't touch.
The strength looks broad-based rather than freakish: its average (+3.9%) and median (+5.6%) sit close together, so no single blow-out year is flattering the figure. Better still, that strength is the stock's own and not just a buoyant market — November has outpaced the S&P 500 by +1.6 points on average. Few peers keep such company in November — the typical stock clears it just 62% of the time.
It doesn't stand entirely alone — January, May, and June have leaned firm as well, if less emphatically. At the other end of the calendar, February has been the soft spot — the weakest of 5 months that average a loss (−2.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in September, March, and April. Its roughest month on record was a −15.1% January in 2022 — a reminder of how hard even a seasonal name can fall.
Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
For a stock this dependable in November, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With a short 6-year record, the signal is best held loosely.
Short answers on the stock's best month (November), its worst (February), and whether it really trades seasonally.
Yes, to a moderate degree. Since 2020 its best month (November, +3.9%) has run well ahead of its worst (February, −2.2%) — the heatmap above shows how steady that gap has been year to year.
November has been the strongest, averaging +3.9% and closing higher in 5 of 6 years since 2020.
It's the weakest, averaging −2.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade